TheraRadar
← Back
Data updated: Mar 29, 2026

SERVIER

OncologyCardiovascularGastroenterology
Pharma

SERVIER is a pharmaceutical company focused on Oncology, Cardiovascular, Gastroenterology. Key products include TIBSOVO.

2018
Since
2
Drugs
-
Trials
2
Approved (2yr)

Key Drugs

TIBSOVO
ivosidenib
Oncology
Mutant IDH1 3 indications · 2018
VORANIGO
vorasidenib
IDH1 2 indications · 2024

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

VORANIGO 2025-04-08
Labeling
VORANIGO 2024-08-06
Type 1 - New Molecular Entity
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 81%
1 drugs Phase 3: 3 Phase 2: 1 Phase 1: 6
Cardiovascular 13%
0 drugs Phase 3: 1
Gastroenterology 6%
0 drugs Phase 1: 2

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Gastroenterology
Novartis big-pharma
Oncology, Cardiovascular
WAYLIS THERAP big-pharma
Oncology, Cardiovascular, Gastroenterology
Merck big-pharma
Oncology, Cardiovascular
Baxter specialty
Cardiovascular, Oncology